Project Grant R21DA062828

Award Date 4/15/25
Completion Date 3/31/27
Dollars Obligated $272K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This federal Project Grant award, totaling $373,300.00, was made by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant aims to study the role of the nucleus accumbens core (NAc) in learning the association between environmental cues and rewards, which is critical for understanding substance use disorder. Specifically, the research will use optogenetic inhibition and two-photon imaging techniques in mice to investigate how...
This $492,000 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to elucidate the genetic and epigenetic mechanisms underlying cocaine addiction using a multidisciplinary approach. The key objectives are to: 1) conduct high-resolution epigenomic profiling to uncover cell-type and circuit-specific changes after cocaine self-administration in mice, 2) leverage the Hybrid Mouse Diversity Panel to...
This federal Project Grant award for $249,236 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research into the role of chromatin regulation and BDNF expression in the ventral tegmental area of the brain in driving persistent cocaine-seeking behaviors. The study aims to define the chromatin architecture changes in dopamine neurons that occur during forced abstinence from chronic cocaine exposure, and then use...
This $1,373,618 federal Project Grant award was provided by the National Institute on Drug Abuse (NIDA) under CFDA Program 93.279 - Drug Use and Addiction Research Programs. The grant supports a 5-year mechanistic research study to further validate a human sign-/goal-tracking paradigm and identify neurobehavioral signatures associated with sign- and goal-tracking behaviors in emerging adults. This research aims to advance understanding of individual differences in addiction liability, a critical...
This $358,012 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to investigate the circuit-specific synaptic plasticity mechanisms in the nucleus accumbens (NAc) evoked by inhibition of angiotensin-converting enzyme (ACE). The primary goal is to determine which specific excitatory and inhibitory presynaptic inputs to NAc medium spiny neurons (MSNs) exhibit ACE inhibition-induced long-term...
This $810,668 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to evaluate an immunotherapeutic compound called DRHQ as a potential treatment for stimulant use disorder, specifically methamphetamine addiction. The primary objective is to assess DRHQ's effects on drug-seeking behavior, cognitive function, and inflammation in preclinical animal models of stimulant use disorder. The research...
This $2,543,654 Project Grant award from the National Institute on Drug Abuse (NIDA), under the CFDA 93.279 Drug Use and Addiction Research Programs, will support research at Virginia Commonwealth University (VCU) to uncover the cell-type-specific brain molecular processes that distinguish stimulant versus opioid addiction. The researchers will use novel synthetic transcription factors (TFs) delivered to the mouse nucleus accumbens (NAc) to investigate how stimulant versus opioid exposure...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will provide $1,478,199 to the University of California, San Diego (UCSD) to investigate the role of different interneurons in the infralimbic (ventral) cortex for the seeking and extinction of cocaine after withdrawal. The 5-year project, running from July 1, 2024 to April 30, 2029, will use multiphoton photon microscopy to directly monitor the activity of...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $477,000.00 in funding to the University of California, San Diego (UCSD) for a 2-year period from September 1, 2024 to August 31, 2026. The purpose of this grant is to utilize cryo-correlative light and electron microscopy (cryo-CLEM) and cryo-electron tomography (cryo-ET) techniques to investigate the molecular architecture and organization of the...
This federal Project Grant award of $445,500.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to identify and characterize conserved regulators of drug-induced plasticity in the nervous system of the nematode Caenorhabditis elegans. The researchers at the University of Alabama at Birmingham will generate comprehensive molecular, behavioral, and neuronal activity atlases in response to acute and chronic...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop new ways to target the G9A and GLP enzymes and understand their role in stimulant addiction. The $272,395 award, effective from April 15, 2025 to March 31, 2027, will be carried out by the Regents of the University of California, San Francisco (UCSF). The key objectives are: 1) to identify specific surfaces on the G9A/GLP enzyme complex that can be targeted for future small molecule therapies, and 2) to determine how the different G9A/GLP enzyme dimers contribute to addiction phenotypes. This will be accomplished through structural analyses using cryo-electron microscopy, cross-linking mass spectrometry, and biochemical characterization of G9A/GLP mutants. The findings will provide critical insights into the molecular mechanisms by which these epigenetic regulators influence addiction, paving the way for the development of targeted therapeutic approaches.

Generated 4/29/25, 1:51 AM